Loss to follow‐up: A significant barrier in the treatment cascade with direct‐acting therapies
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13228
Abstract: Effectiveness of direct‐acting antiviral (DAA) therapies could be influenced by patient characteristics such as comorbid conditions, which could lead to premature treatment discontinuation and/or irregular medical follow‐ups. Here, we evaluate loss to follow‐up and treatment… read more here.
Keywords: rbv; follow significant; treatment; loss follow ... See more keywords